Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TAS 106

Next Previous
X
Search
Drug Profile

TAS 106

Alternative Names: ECyd; Ethynylcytidine; SB 596168; TAS-106

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Taiho Pharmaceutical
  • Class Antineoplastics; Ribonucleosides; Small molecules
  • Mechanism of Action Antimetabolites; Cytidine triphosphate synthetase inhibitors; DNA-directed RNA polymerase inhibitors; Ribonucleotide reductase inhibitors; RNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Head and neck cancer; Solid tumours

Most Recent Events

  • 30 Sep 2011 Phase-I/II clinical trials in Solid tumours in USA (IV)
  • 05 Jul 2007 Data presented at the 43rd Annual Meeting of the American Society of Clinical Onclology (ASCO-2007) added to the adverse events, pharmacokinetics and Cancer therapeutic trials sections ,
  • 29 Dec 2003 This compound is still in active development

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top